Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ovarian Cancer

Ovarian Cancer

24 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ovarian Cancer

371 trials tracked for Ovarian Cancer: 43 in phase 3 or 4 and 21 with published results. The most-cited published study has 419 citations.

371Trials tracked
43Phase 3 & 4
0Recruiting
21With published results
Phase distribution
Phase 4 8 Phase 3 35 Phase 2 256 Phase 1 39 Other / NA 33
  1. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 419 cited
  2. Phase 3 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Completed · 417 cited
  3. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 303 cited
  4. Phase 3 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments Completed · 297 cited
  5. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 262 cited
  6. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 235 cited
Show 44 more trials
  1. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 234 cited
  2. Phase 3 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed · 195 cited
  3. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 195 cited
  4. Phase 3 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer Completed · 171 cited
  5. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 145 cited
  6. Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Completed · 131 cited
  7. Phase 4 Tumor Gene Expression in Women With Ovarian Cancer Completed · 91 cited
  8. Phase 3 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed · 72 cited
  9. Phase 3 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed · 70 cited
  10. Phase 3 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed · 64 cited
  11. Phase 3 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Completed · 58 cited
  12. Phase 3 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed · 43 cited
  13. Phase 3 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Completed · 25 cited
  14. Phase 3 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 19 cited
  15. Phase 3 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed · 18 cited
  16. Phase 4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Completed
  17. Phase 4 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed
  18. Phase 4 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Completed
  19. Phase 4 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer Completed
  20. Phase 4 A Study of Serum Folate Levels in Patients Treated With Olaparib Completed
  21. Phase 4 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed
  22. Phase 4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed
  23. Phase 3 Accelerating Gastrointestinal Recovery Completed
  24. Phase 3 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed
  25. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
  26. Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
  27. Phase 3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  28. Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
  29. Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  30. Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed
  31. Phase 3 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed
  32. Phase 3 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed
  33. Phase 3 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed
  34. Phase 3 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Completed
  35. Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  36. Phase 3 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed
  37. Phase 3 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed
  38. Phase 2 RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  39. Phase 2 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Completed
  40. Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Completed
  41. Phase 2 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed
  42. Phase 2 Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors Completed
  43. Phase 2 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer Completed
  44. Phase 2 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Completed

Showing the 50 most-cited and recently-updated of 371 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Ovarian Cancer: what the trials found

Mirvetuximab soravtansine has demonstrated clinical activity in ovarian cancer, with reported CA-125 confirmed clinical response rates of 74.5% 5 and objective response rates (ORR) of 22% compared to 12% in a separate trial 20.

Olaparib is established as an intervention for this condition, showing significant improvements in progression-free survival (PFS) with a median of 13.4 months versus 9.2 months (p=0.013) and a superior objective response rate (ORR) of 109% vs 37% (p=0.002) 19. Clinical assessments of quality of life using FACT-O, FACIT-F, and FLIE scales were also recorded for Olaparib 14.

Paclitaxel has been evaluated in large-scale trials; while it showed a statistically significant improvement in progression-free survival specifically within the PD-L1-positive subpopulation (p=0.0376), there was no significant difference in overall survival for the intent-to-treat population 17.

Other established interventions include bevacizumab, which showed comparable median progression-free survival across study arms (p=0.341) 22, and sodium thiosulfate 21. Additional supportive or adjunctive treatments include dexamethasone 9, aspirin 12, fosaprepitant 15, and pegylated liposomal doxorubicin hydrochloride 16.

Tranexamic acid was shown to significantly reduce perioperative bleeding volume (p=0.03) 13. Regarding monitoring, folic acid supplementation is noted in the context of Olaparib use, where some patients developed folate deficiency or decreased hemoglobin levels 10.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a 95% progression-free survival rate at 6 months when measured from the start of pre-trial weekly paclitaxel, compared to 5.0% for maintenance pembrolizumab alone 2.
  • Metformin hydrochloride did not show statistically significant differences in progression-free survival (p=0.31), time to CA-125/radiological progression (p=0.89), or overall survival (p=0.21) 3.
  • Other emerging interventions include NT-I7 4, Pegylated Liposomal Doxorubicin + SL-172154 6, High-Purity Type-I Collagen Scaffold 7, and Acupressure 8.

For the clinician treating this condition

  • Mirvetuximab soravtansine shows significant clinical response rates in patients with ovarian cancer [5, 20].
  • Olaparib provides a statistically significant improvement in progression-free survival and objective response rates compared to standard controls 19.
  • Tranexamic acid is effective in reducing perioperative bleeding volume 13.
  • Paclitaxel shows specific efficacy in the PD-L1-positive subpopulation 17.

AI synthesis of 19 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
BRCA1 or BRCA2 mutations correlate with improved survival and platinum sensitivity in ovarian cancer
Oncology Sys. Review
BRCA1 or BRCA2 mutations correlate with improved survival and platinum sensitivity in ovarian cancer BRCA Mutations Linked to Better Ovarian Cancer Survival
This systematic review examines the impact of BRCA1 and BRCA2 mutation status on treatment outcomes in ovarian cancer patients. The review f…
Women with ovarian cancer and BRCA mutations may live longer and respond better to certain treatments, a review finds.
Frontiers Sep 10, 2026
Impact of Lifestyle and Nursing Interventions on Quality of Life in Gynecologic Cancers
Oncology Meta-analysis
Impact of Lifestyle and Nursing Interventions on Quality of Life in Gynecologic Cancers Nursing and lifestyle support improve quality of life for ovarian cancer
A meta-analysis of 915 patients indicates that lifestyle and nursing interventions significantly improve quality of life specifically in ova…
Specialized nursing and lifestyle programs can significantly improve the quality of life for women living with ovarian cancer.
Sep 4, 2026
Olaparib maintenance therapy significantly improves progression-free survival in advanced ovarian cancer patients
Oncology Meta-analysis
Olaparib maintenance therapy significantly improves progression-free survival in advanced ovarian cancer patients Olaparib Maintenance Therapy Delays Progression in Advanced Ovarian Cancer
This meta-analysis of randomized trials evaluates olaparib maintenance therapy for advanced ovarian cancer following platinum-based chemothe…
Olaparib maintenance therapy significantly delays disease progression in advanced ovarian cancer, especially for patients with specific gene…
Sep 2, 2026
ICI-based combinations show measurable but heterogeneous activity in platinum-resistant ovarian cancer
Oncology Meta-analysis
ICI-based combinations show measurable but heterogeneous activity in platinum-resistant ovarian cancer Combination therapy shows mixed results for advanced ovarian cancer
This systematic review and meta-analysis of ICI-based combination therapies in platinum-resistant ovarian cancer found an ORR of 21.9% and a…
New data reveals that while some patients with resistant ovarian cancer see stable disease, the effectiveness of certain drug combinations v…
Frontiers Aug 27, 2026
Lutein, beta-carotene, and vitamin D are associated with lower risks of several gynecological and breast cancers
Nutrition & Obesity Medicine Meta-analysis
Lutein, beta-carotene, and vitamin D are associated with lower risks of several gynecological and breast cancers Specific nutrients show linked lower risks for certain women's cancers
This meta-analysis evaluates the association between various nutritional exposures and the risk of breast, ovarian, and uterine cancers. The…
Research identifies how vitamins like D, E, and minerals like calcium may be linked to lower risks of breast, ovarian, and uterine cancers.
medRxiv Aug 24, 2026
Community governance models for nutrition-oriented care aim to reduce survival disparities across multiple cancers
Allergy & Immunology Sys. Review
Community governance models for nutrition-oriented care aim to reduce survival disparities across multiple cancers Community governance can improve nutrition care for cancer patients
This mini review explores the role of community governance in integrating nutritional support into oncology services for breast, cervical, o…
Newer policy models aim to bridge the gap in nutrition care, helping women with various cancers access better food security and support.
Frontiers Aug 18, 2026
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
Allergy & Immunology Sys. Review
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers Protein D shows promise in diagnosing and treating several cancers
This narrative review explores the role of Surfactant protein D (SP-D) across multiple malignancies, including lung adenocarcinoma and breas…
A specific protein called Surfactant protein D may help doctors identify lung cancer and fight cells in breast and leukemia cases.
Frontiers Aug 15, 2026
Metachronous pancreatic metastasis from ovarian cancer is rare, mostly high-grade serous
Oncology Sys. Review
Metachronous pancreatic metastasis from ovarian cancer is rare, mostly high-grade serous Ovarian cancer can spread to pancreas, rare review finds
This systematic review of 7 studies (8 cases) found that metachronous pancreatic metastasis from ovarian cancer is rare and most often origi…
A rare spread of ovarian cancer to the pancreas may be treatable with surgery or chemo, but evidence is thin.
Frontiers Aug 13, 2026
Tumor microenvironment drives ovarian cancer progression and subtype-specific outcomes
Urology Sys. Review
Tumor microenvironment drives ovarian cancer progression and subtype-specific outcomes Tumor Environment Influences Treatment Outcomes in Ovarian Cancer
This narrative review examines the tumor microenvironment (TME) in ovarian cancer subtypes, highlighting its central role in progression, me…
Understanding the unique environment surrounding tumors and different cancer subtypes may help doctors identify better ways to treat ovarian…
Frontiers Aug 4, 2026
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer
Oncology Meta-analysis
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer PARP Inhibitors Show Improved Survival for Advanced Ovarian Cancer
This network meta-analysis of randomized trials evaluates PARP inhibitors for advanced ovarian cancer. The analysis indicates that olaparib,…
New data shows PARP inhibitors like olaparib and niraparib may improve survival for both younger and older patients with advanced ovarian ca…
Frontiers Jul 9, 2026
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
Nutrition & Obesity Medicine Sys. Review
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types Sugar sweetened drinks may increase risk of several cancer types
This meta-analysis of 51 cohort studies evaluates the link between sugar sweetened beverages (SSBs), artificially sweetened beverages (ASBs)…
New research suggests a link between sugar-sweetened beverages and an increased risk of certain cancers, including pancreatic and colorectal…
medRxiv Jul 7, 2026
Radiomics and clinical data combined in AI models achieve 0.86 AUC for predicting ovarian cancer metastasis
Radiology & Imaging Meta-analysis
Radiomics and clinical data combined in AI models achieve 0.86 AUC for predicting ovarian cancer metastasis Artificial intelligence helps predict where ovarian cancer has spread
This systematic review and meta-analysis analyzed medical image-based artificial intelligence models for predicting metastasis in patients w…
New analysis shows that AI models combining medical images and patient data can accurately predict if ovarian cancer has spread to other org…
Jul 6, 2026

Questions about Ovarian Cancer

Is [68Ga]Ga-FAPI PET imaging accurate for diagnosing Ovarian Cancer?

Yes, [68Ga]Ga-FAPI PET imaging is highly accurate for diagnosing ovarian cancer, especially for detecting peritoneal and lymph node metastases, and may outperform standard FDG PET in certain settings.

Full answer →
Do PARP inhibitors improve survival for patients with BRCA-mutated Ovarian Cancer?

Yes, PARP inhibitors significantly improve progression-free survival for patients with BRCA-mutated ovarian cancer, with some studies also showing overall survival benefits.

Full answer →
Can relacorilant and nab-paclitaxel help patients with platinum-resistant Ovarian Cancer?

Yes, relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer, based on phase 2 and phase 3 trial results.

Full answer →
Does taking birth control pills lower the risk of getting Ovarian Cancer?

Yes, taking birth control pills is associated with a lower risk of ovarian cancer, especially with longer use.

Full answer →

All Ovarian Cancer Articles